ArticleDiscover oncology2026
Establishiment of PANoptosis-related prognostic signature and experimental identification of SIGLEC1 as an oncogenic biomarker in endometrial cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEndometrial cancer (EC) is a prevalent gynecological malignancy with prognoses varying significantly across molecular subtypes. PANoptosis, a recently identified mode of cell death, has been implicated in tumor progression, yet its role in EC remains understudied. This study aims to explore the prognostic and immunomodulatory functions of PANoptosis-related genes (PANRGs) in EC and their associations with molecular subtypes, thereby facilitating targeted and precision therapy.
methodsEC expression profiles and clinical data were acquired from uterine corpus endometrial carcinoma (UCEC) project of TCGA database. PANRGs were identified via Gene Set Variation Analysis (GSVA) and Weighted Gene Co-expression Network Analysis (WGCNA). Prognostic feature genes were screened using LASSO, Random Forest, GBM, and XGBOOST algorithms to construct a risk signature. Mutation profiles, immune characteristics, and molecular subtype associations across risk groups were analyzed, with functional emphasis on key signature genes. CCK-8 and Transwell assays were used to confirm the biological effects of key markers on EC cells, while Western blotting assays were employed to illustrate the underlying mechanisms.
resultsGSVA and WGCNA identified 40 differentially expressed PANRGs. Machine learning algorithms further filtered out four prognostic genes (FOXP3, SIGLEC1, RASSF4, BATF). The low-risk group exhibited significantly better overall survival than the high-risk group, with distinct mutation and immune regulation profiles. Consensus clustering analysis revealed associations between these differences and EC molecular subtypes. SIGLEC1, with its poor prognostic correlation, promoted the growth of EC cells as well as the invasion and migration ability, and knocking down SIGLEC1 led to apoptosis, pyroptosis and necroptosis.
conclusionPANRGs-based prognostic signatures distinguished EC clinical outcomes and correlated with immune regulation and mutation profiles. SIGLEC1 exerted an oncogenic effect by resisting panoptosis and served as a prognostic and immune marker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.